Literature DB >> 31755139

Ruxolitinib for steroid-refractory acute graft-versus-host disease.

Wael Toama1, Mark Fiala2, Iskra Pusic2, Peter Westervelt2, John F Dipersio2, Mark Schroeder2.   

Abstract

Entities:  

Year:  2019        PMID： 31755139      PMCID： PMC7446711          DOI： 10.1111/tri.13560

Source DB:  PubMed          Journal:  Transpl Int        ISSN： 0934-0874            Impact factor:   3.782


× No keyword cloud information.
  4 in total

1.  Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.

Authors:  Hanna Jean Khoury; Amelia A Langston; Vamsi K Kota; Jennifer A Wilkinson; Iskra Pusic; Anand Jillella; Stephanie Bauer; Audrey S Kim; Danielle Roberts; Zaid Al-Kadhimi; Imre Bodo; Elliott Winton; Martha Arellano; John F DiPersio
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

2.  What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score.

Authors:  Margaret L MacMillan; Todd E DeFor; Daniel J Weisdorf
Journal:  Br J Haematol       Date:  2012-04-06       Impact factor: 6.998

3.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

Authors:  Margaret L MacMillan; Daniel J Weisdorf; John E Wagner; Todd E DeFor; Linda J Burns; Norma K C Ramsay; Stella M Davies; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

4.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.